Solventum Reports Second Quarter 2025 Financial Results

Reported sales increased 3.9%; organic sales increased 2.8% Increases full year organic sales growth outlook to +2.0% to +3.0% Increases full year earnings per share outlook to $5.80 to $5.95 , /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Sales increased 3.9% to $2.2 billion; up 2.8% on an organic basis GAAP diluted earnings per share of $0.51; adjusted diluted earnings per share of $1.69 Operating cash flow of $169 million; free cash flow of $59 million "Our solid second quarter fiscal year 2025 results mark five consecutive quarters of positive sales volume growth since implementing our transformation strategy," said Bryan Hanson, chief executive officer of Solventum. "Given the continued and underlying momentum in our business and markets, we have raised our full year 2025 guidance at the top and bottom line reflecting confidence in our strategy and execution." Second Quarter and First Six Months 2025 Financial Results Three months ended June 30, Six months ended June 30, (Dollars in millions, except per share amounts) 2025 2024 Year over year change 2025 2024 Year over year change Net sales $ 2,161 $ 2,081 3.9 % $ 4,231 $ 4,097 3.3 % Selling, general and administrative expenses $ 772 $ 701 10.1 % $ 1,541 $ 1,297 18.8 % Research and development expenses $ 189 $ 192 (1.6) % $ 381 $ 387 (1.6) % Operating income margin 9.9 % 11.7 % (180) bps 8.7 % 15.3 % (660) bps Adjusted operating income margin1 21.9 % 20.7 % 120 bps 20.8 % 22.3 % (150) bps Net income $ 90 $ 89 1.1 % $ 227 $ 326 (30.4) % Diluted earnings per share $ 0.51 $ 0.51 — % $ 1.30 $ 1.88 (30.9) % Adjusted diluted earnings per share1 $ 1.69 $ 1.56 8.3 % $ 3.03 $ 3.64 (16.8) % Net cash provided by operating activities $ 169 $ 355 (52.4) % $ 198 $ 797 (75.2) % Free cash flow1 $ 59 $ 297 (80.1) % $ (21) $ 637 (103.3) % Organic sales growth in the quarter reflect positive performance from all segments, primarily driven by the MedSurg and HIS segments. GAAP and adjusted operating income margin declined due to lower gross margins, including the impact from 3M supply agreement mark-up, and an increase in operating expenses related to public company stand-up costs and growth investments. 1 Represents non-GAAP financial measure; see the "Non-GAAP Financial Measures" section for applicable information. Segment and Total Company Net Sales for Second Quarter* Three months ended June 30, Increase/(Decrease) (Dollars in millions) 2025 2024 Reported Growth Currency Impact Constant Currency2 Other3 Organic Growth Advanced Wound Care $ 467 $ 460 1.7 % 0.9 % 0.8 % — % 0.8 % Infection Prevention and Surgical Solutions 750 702 6.9 1.0 5.9 — 5.9 MedSurg 1,218 1,162 4.8 0.9 3.9 — 3.9 Dental Solutions 338 331 2.3 1.6 0.6 — 0.7 Health Information Systems 339 328 3.4 0.2 3.2 — 3.2 Purification and Filtration 252 238 5.4 2.3 3.1 — 3.1 Corporate and Unallocated4 15 22 NM NM NM NM NM Total Company $ 2,161 $ 2,081 3.9 % 1.1 % 2.8 % — % 2.8 % *Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum. The Company's use of the term "NM" reflects results not considered to be material due to either not having material activity in the comparable prior years or is not meaningful. 2 Constant currency represents the change in net sales absent the impact on sales from foreign currency translation. 3 Other represents sales impact from acquisitions and divestitures measured separately for the first 12 months post-transaction. Acquisitions include non-healthcare related supply agreements that conveyed from 3M to the Company at Spin-Off and sales from new supply agreements with 3M that commenced at Spin-Off. Divestiture impacts include certain health care businesses retained by 3M India in connection with the Spin-Off. 4 Corporate and unallocated includes sales related to product supplied to 3M and other supply agreements related to legacy 3M business and assumed by the company at Spin-Off. Total sales change is calculated based on reported sales results. The components of sales change include organic local-currency sales, translation, and other. Organic local-currency sales include both organic volume impacts (which excludes acquisition and divestiture impacts, in addition to supply agreement and impacts) and selling price changes. Other represents sales impact from acquisitions and divestitures measured separately for the first 12 months post-transaction. Divestiture impacts include lost sales from the company's dental anesthetics business that was sold in August 2023 and certain health care businesses retained by 3M India in connection with the spin-off. Full-Year 2025 GuidanceSolventum is updating its full year 2025 guidance to reflect underlying business performance and flexibility to navigate the dynamic macroeconomic environment as follows: Increased organic sales growth range to +2.0% to +3.0% (+2.5% to +3.5% excluding ~50 bps of SKU exit impact); from prior range of +1.5% to +2.5% Increased adjusted EPS range to $5.80 to $5.95; from prior range of $5.45 to $5.65 Free cash flow in the range of $450M to $550M; no change Note: Full year 2025 guidance includes the Purification & Filtration segment. On June 25, 2025, we announced amended terms of the sale of our Purification & Filtration segment, whereby Solventum will retain ownership of the Drinking Water Filtration business. We will update our annual guidance for related impacts after the transaction closes. Organic sales, adjusted diluted EPS and free cash flow amounts included in Solventum's full-year guidance are non-GAAP financial measures. Solventum does not provide reconciliations of the forward-looking non-GAAP financial measures to the respective GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items, such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures, and the timing and magnitude of restructuring activities, among other items. Please note Solventum's Q1 2024 results were reported on a carve-out basis. See the "Non-GAAP Financial Measures" section for explanations of our non-GAAP financial measures. Earnings Conference CallSolventum will host a conference call today, Aug. 7, at 4:30 p.m. Eastern Time to discuss its second quarter financial results and provide an update on its business. The conference call can be accessed via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers, using the conference ID 6342275. A replay of the webcast, along with the earnings press release, slides highlighting the results, and supplemental financial disclosures, will also be available at the same link on the Investor Relations section of the company's website. Forward-Looking Statements This news release contains forward-looking information about Solventum's financial results and estimates and business prospects, including guidance for 2025, that contain or incorporate by reference statements that relate to future events and expectations and, as such, constitute forward-looking statements that involve risk and uncertainties. Forward-looking statements include those containing such words as "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "guidance," "intends," "may," "outlook," "plans," "projects," "seeks," "sees," "should," "targets," "will," "would," or other words of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially from those described in our forward looking statements are the following: (1) the effects of, and changes in, worldwide economic, political, regulatory, international, trade and geopolitical conditions, natural disasters, war, public health crises, and other events beyond Solventum's control; (2) operational execution risks; (3) damage to Solventum's reputation or its brands; (4) risks from acquisitions, strategic alliances, divestitures and other strategic events, including the divestiture of our Purification and Filtration business; (5) Solventum's business dealings involving third-party partners in various markets; (6) Solventum's ability to access the capital and credit markets and changes in Solventum's credit ratings; (7) exposure to interest rate and currency risks; (8) the highly competitive environment in which Solventum operates and consolidation in the healthcare industry; (9) reduction in customers' research budgets or government funding; (10) the timing and market acceptance of Solventum's new product and service offerings; (11) ongoing working relationships with certain key healthcare professionals; (12) changes in reimbursement practices of governments or private payers or other cost containment measures; (13) Solventum's ability to obtain components or raw materials supplied by third parties and other manufacturing and related supply chain difficulties, interruptions, and disruptive factors; (14) legal and regulatory proceedings and legal compliance risks (including third-party risks) with regards to antitrust, FCPA and other anti-bribery laws, environmental laws, anti-kickback and false claims laws, privacy laws, product liability claims, tax laws, and other laws and regulations in the United States and other countries in which Solventum operates; (15) potential liabilities related to per-and polyfluoroalkyl substances, collectively known as "PFAS"; (16) risks related to the highly regulated environment in which Solventum operates; (17) risks associated with product liability claims; (18) climate change and measures to address climate change; (19) security breaches and other disruptions to information technology infrastructure; (20) Solventum's failure to obtain, maintain, protect, or effectively enforce its intellectual property rights; (21) pension and postretirement obligation liabilities; (22) any failure by 3M Company ("3M") to perform any of its obligations under the various separation agreements entered into in connection with the separation of Solventum from 3M (the "Spin-Off"); (23) any failure to realize the expected benefits of the Spin-Off; (24) a determination by the IRS or other tax authorities that the Spin-Off or certain related transactions should be treated as taxable transactions; (25) financing transactions undertaken in connection with the Spin-Off and risks associated with additional indebtedness; (26) the risk that incremental costs of operating on a standalone basis (including the loss of synergies), costs of restructuring transactions and other costs incurred in connection with the Spin-Off will exceed Solventum's estimates; and (27) the impact of the Spin-Off on Solventum's businesses and the risk that the Spin-Off may be more difficult, time-consuming or costly than expected, including the impact on Solventum's resources, systems, procedures and controls, diversion of management's attention and the impact on relationships with customers, suppliers, employees and other business counterparties. The above list is not exhaustive or necessarily set forth in the order of importance. Forward-looking statements are based on certain assumptions and expectations of future events and trends, and actual future results and trends may differ materially from historical results or those reflected in any such forward-looking statements depending on a variety of factors. A further description of these factors is located under "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" in Solventum's periodic reports on file with the U.S. Securities & Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information, future events or otherwise, except as required by applicable law. Non-GAAP Financial MeasuresIn addition to reporting financial results in accordance with U.S. GAAP, Solventum also provides non-GAAP measures that we use, and plan to continue using, when monitoring and evaluating operating performance and measuring cash available to invest in our business. The adjusted measures are not in accordance with, nor are they a substitute for, GAAP measures. These non-GAAP financial measures are supplemental measures of our performance and our liquidity that we believe help investors understand our underlying business performance and Solventum uses these measures as an indication of the strength of Solventum and its ability to generate cash. Solventum calculates forward-looking non-GAAP financial measures, including organic sales growth, adjusted operating income, adjusted operating income margin, adjusted effective tax rate, adjusted diluted earnings per share, and free cash flow based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. Solventum does not provide reconciliations of these forward-looking non-GAAP financial measures to the respective GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures, and the timing and magnitude of restructuring activities, among other items. The timing and amounts of these items are uncertain and could have a material impact on Solventum's results in accordance with GAAP. The Q2 2025 financial statements and financial information, including reconciliations of non-GAAP financial measures, are available on Solventum's website: investors.solventum.com. About Solventum At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com. Solventum Corporation CONDENSED CONSOLIDATED STATEMENTS OF INCOME* (Dollars in millions, except per-share data) (Unaudited) Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Net sales of product $ 1,668 $ 1,605 $ 3,265 $ 3,158 Net sales of software and rentals 493 476 966 939 Total net sales 2,161 2,081 4,231 4,097 Cost of product 865 823 1,700 1,548 Cost of software and rentals 121 121 242 240 Gross profit 1,175 1,137 2,289 2,309 Selling, general and administrative expenses 772 701 1,541 1,297 Research and development expenses 189 192 381 387 Operating income 214 244 367 625 Interest expense, net 103 114 207 153 Other expense (income), net 8 34 19 47 Income before income taxes 103 96 141 425 Provision for (benefit from) income taxes 13 7 (86) 99 Net Income $ 90 $ 89 $ 227 $ 326 Earnings per share: Basic earnings per share $ 0.52 $ 0.51 $ 1.31 $ 1.89 Diluted earnings per share 0.51 0.51 1.30 1.88 Weighted-average number of share outstanding: Basic 174.1 173.2 173.9 172.9 Diluted 175.2 173.5 175.0 173.1 *Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum. Solventum Corporation CONDENSED CONSOLIDATED BALANCE SHEETS* (Dollars in millions, except per-share data) (Unaudited) June 30, December 31, 2025 2024 Assets Current assets Cash and cash equivalents $ 492 $ 762 Accounts receivable — net of allowances of $87 and $86 1,065 1,044 Due from related parties 190 185 Inventories Finished goods 553 539 Work in process 173 190 Raw materials and supplies 236 236 Total inventories 962 965 Other current assets 331 293 Current assets held for sale 168 — Total current assets 3,208 3,249 Property, plant and equipment — net 1,313 1,622 Goodwill 5,274 6,377 Intangible assets — net 2,302 2,544 Other assets 917 665 Non-current assets held for sale 2,060 — Total assets $ 15,074 $ 14,457 Liabilities Current liabilities Short-term borrowings and current portion of long-term debt $ — $ 200 Accounts payable 643 618 Due to related parties 355 272 Unearned revenue 557 572 Other current liabilities 1,011 1,041 Current liabilities held for sale 54 — Total current liabilities 2,620 2,703 Long-term debt 7,815 7,810 Pension and postretirement benefits 354 350 Deferred income taxes 231 225 Other liabilities 371 410 Non-current liabilities held for sale 38 — Total liabilities $ 11,429 $ 11,498 Equity Common stock par value, $0.01 par value, 750,000,000 shares authorized $ 2 $ 2 Shares issued and outstanding - June 30, 2025: 173,387,361 Shares issued and outstanding - December 31, 2024: 172,785,606 Additional paid-in capital 3,806 3,771 Retained earnings 468 242 Accumulated other comprehensive income (loss) (631) (1,056) Total equity 3,645 2,959 Total liabilities and equity $ 15,074 $ 14,457 *Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum. Solventum Corporation CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS* (Dollars in millions) (Unaudited) Six months ended June 30, (Millions) 2025 2024 Cash Flows from Operating Activities Net income $ 227 $ 326 Adjustments to reconcile net income to net cash provided by operating activities Depreciation and amortization 251 272 Postretirement benefit plan expense 32 19 Stock-based compensation expense 83 60 Deferred income taxes (177) (56) Changes in assets and liabilities Accounts receivable (15) 70 Due from related parties 4 131 Inventories (77) (57) Accounts payable 23 132 Due to related parties (6) (169) Accrued compensation (47) 45 All other operating activities (100) 24 Net cash provided by operating activities 198 797 Cash Flows from Investing Activities Purchases of property, plant and equipment (219) (160) Other — net (5) — Net cash used in investing activities (224) (160) Cash Flows from Financing Activities Repayment of debt (200) — Net transfers to 3M (30) (8,247) Proceeds from long-term debt, net of issuance costs — 8,303 Other — net (19) 10 Net cash (used in) provided by financing activities (249) 66 Effect of exchange rate changes on cash and cash equivalents 7 — Net increase (decrease) in cash and cash equivalents (268) 703 Cash and cash equivalents at beginning of period 762 194 Less: Cash and cash equivalents within held for sale (2) — Cash and cash equivalents at end of period $ 492 $ 897 *Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum. Solventum Corporation SALES CHANGE ANALYSIS (Dollars in millions) (Unaudited) Segment and Total Company Net Sales for the First Six Months* Six months ended June 30, Increase/(Decrease) (Dollars in millions) 2025 2024 Reported Growth Currency Impact Constant Currency2 Other3 Organic Growth Advanced Wound Care $ 915 $ 901 1.6 % (0.1) % 1.7 % (0.1) % 1.8 % Infection Prevention and Surgical Solutions 1,460 1,380 5.8 (0.4) 6.2 (0.8) 7.0 MedSurg 2,375 2,281 4.1 (0.3) 4.4 (0.5) 4.9 Dental Solutions 667 666 0.1 (0.2) 0.3 (0.3) 0.6 Health Information Systems 667 645 3.5 — 3.5 — 3.5 Purification and Filtration 494 483 2.2 0.1 2.1 (0.5) 2.6 Corporate and Unallocated4 28 22 NM NM NM NM NM Total Company $ 4,231 $ 4,097 3.3 % (0.2) % 3.5 % — % 3.5 % *Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum. The Company's use of the term "NM" reflects results not considered to be material due to either not having material activity in the comparable prior years or is not meaningful. 2 Constant currency represents the change in net sales absent the impact on sales from foreign currency translation. 3 Other represents sales impact from acquisitions and divestitures measured separately for the first 12 months post-transaction. Acquisitions include non-healthcare related supply agreements that conveyed from 3M to the Company at Spin-Off and sales from new supply agreements with 3M that commenced at Spin-Off. Divestiture impacts include certain health care businesses retained by 3M India in connection with the Spin-Off. 4 Corporate and unallocated includes sales related to product supplied to 3M and other supply agreements related to legacy 3M business and assumed by the company at Spin-Off. Solventum Corporation and SubsidiariesBUSINESS SEGMENTS – (CONTINUED)*(Unaudited) The Company's operating activities are managed through four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. MedSurg provides: advanced wound care products such as negative pressure wound therapy, advanced wound dressings and advanced skin care; and infection prevention and surgical solutions products, such as I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies Original Equipment Manufacturer ("OEM"). Dental Solutions provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents that span the "life of the tooth," including products designed for preventative dental care, direct and indirect restoration, and broad orthodontic needs. Health Information Systems provides healthcare systems with software solutions – including computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. Purification and Filtration includes filters and membranes for biopharmaceutical and medical technologies, microelectronics and food and beverage, as well as filtration for cleaner drinking water. BUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES* Three months ended June 30, 2025 Three months ended June 30, 2024 (Dollars in millions) Net Sales Operating Income Operating Margin % Net Sales Operating Income Operating Margin % Advanced Wound Care $ 467 $ 460 Infection Prevention and Surgical Solutions 750 702 MedSurg 1,218 $ 210 17.3 % 1,162 $ 214 18.4 % Dental Solutions 338 96 28.5 331 93 28.0 Health Information Systems 339 120 35.5 328 111 33.8 Purification and Filtration 252 48 19.2 238 19 8.0 Total business segment operating income 474 437 Corporate and Unallocated: Amortization expense (78) (86) Other Corporate and Unallocated (182) (107) Total Corporate and Unallocated 15 (260) NM 22 (193) NM Total Company $ 2,161 $ 214 9.9 % $ 2,081 $ 244 11.7 % *Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum. The Company's use of the term "NM" reflects results not considered to be material due to either not having material activity in the comparable prior years or is not meaningful. BUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES* Six months ended June 30, 2025 Six months ended June 30, 2024 (Dollars in millions) Net Sales Operating Income Operating Margin % Net Sales Operating Income Operating Margin % Advanced Wound Care $ 915 $ 901 Infection Prevention and Surgical Solutions 1,460 1,380 MedSurg 2,375 $ 416 17.5 % 2,281 $ 435 19.1 % Dental Solutions 667 175 26.2 666 203 30.5 Health Information Systems 667 229 34.3 645 212 32.9 Purification and Filtration 494 83 16.9 483 58 12.0 Total business segment operating income 904 908 Corporate and Unallocated: Amortization expense (159) (173) Other Corporate and Unallocated (377) (110) Total Corporate and Unallocated 28 (536) NM 22 (283) NM Total Company $ 4,231 $ 367 8.7 % $ 4,097 $ 625 15.3 % __________________________________________________________________________________ *Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum. The Company's use of the term "NM" reflects results not considered to be material due to either not having material activity in the comparable prior years or is not meaningful. Solventum CorporationSUPPLEMENTAL FINANCIAL INFORMATIONNON-GAAP MEASURES(Unaudited) In addition to reporting financial results in accordance with U.S. GAAP, the company use non-GAAP financial measures to supplement the financial measures prepared in accordance with U.S. GAAP. These include (1) adjusted operating income and adjusted operating income margin, (2) adjusted diluted earnings per share, and (3) free cash flow. Management believes that these non-GAAP financial measures are useful in evaluating current performance and focusing management on our underlying operational results. There are limitations to the use of the non-GAAP financial measures presented in this information statement. These non-GAAP financial measures are not prepared in accordance with U.S. GAAP nor do they have any standardized meaning under U.S. GAAP. In addition, other companies may use similarly titled non-GAAP financial measures that are calculated differently from the way we calculate such measures. Accordingly, our non-GAAP financial measures may not be comparable to such similarly titled non-GAAP financial measures used by other companies. Management cautions you not to place undue reliance on these non-GAAP financial measures, but instead to consider them with the most directly comparable U.S. GAAP measure. These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation. These non-GAAP financial measures should be considered supplements to, not substitutes for, or superior to, the corresponding financial measures calculated in accordance with U.S. GAAP. The tables below reconcile our non-GAAP financial measures to the nearest financial measure that is in accordance with U.S. GAAP for the periods presented. Adjusted Operating Income, Adjusted Operating Income Margin and Adjusted Earnings Per Share (Non-GAAP measures) Adjusted operating income and adjusted operating income margin are not defined under U.S. GAAP. Therefore, they should not be considered a substitute for earnings data prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. Solventum defines adjusted operating income as operating income excluding the effects of amortization, restructuring costs, Spin-Off and separation-related costs, certain litigation-related costs, and impacts related to the sale of the Purification and Filtration business. Adjusted operating income margin is adjusted operating income divided by the U.S GAAP measure total net sales for the same period. The company believes adjusted operating income and adjusted operating income margin provide investors with visibility into the company's unleveraged, pre-tax operating results and reflects underlying financial performance. However, adjusted operating income should not be construed as inferring that the company's future results will be unaffected by the items for which the measure adjusts. Adjusted diluted earnings per share is not defined under U.S. GAAP. Therefore, it should not be considered a substitute for earnings data prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. Solventum defines adjusted diluted earnings per share as net income excluding the after-tax effects of amortization, restructuring costs, Spin-Off and separation-related costs, certain litigation-related costs, and impacts related to the sale of the Purification and Filtration business and legal entity restructuring costs. The company believes adjusted earnings per share provides investors with improved comparability of underlying operating results and a further understanding and additional transparency regarding how the company evaluates the business. However, adjusted earnings per share should not be construed as inferring that the company's future results will be unaffected by the items for which the measure adjusts. Solventum Corporation SUPPLEMENTAL FINANCIAL INFORMATION NON-GAAP MEASURES – (CONTINUED)* (Unaudited) Three months ended June 30, 2025 (Dollars in millions, except per share amounts) Net sales Cost of Sales5 Gross Margin % Operating Expenses6 Operating Income Operating Income Margin % Non-Operating Expense (Income), net7 Income Before Income Taxes Net Income Attributable to Solventum Diluted EPS Effective Tax Rate GAAP $ 2,161 $ 986 54.4 % $ 961 $ 214 9.9 % $ 111 $ 103 $ 90 $ 0.51 12.5 % Non-GAAP Adjustments: Amortization of acquisition-related intangible assets — — — (78) 78 3.6 — 78 67 0.38 Restructuring costs (a) — (1) 0.1 (7) 8 0.5 — 8 6 0.03 Spin-off and separation-related costs (b) — (33) 1.5 (117) 150 6.9 — 150 115 0.66 Certain litigation-related costs (d) — — — (8) 8 0.4 — 8 6 0.03 Sale of Purification and Filtration-related (e) — — — (15) 15 0.7 — 15 12 0.07 Non-GAAP $ 2,161 $ 952 56.0 % $ 736 $ 474 21.9 % $ 111 $ 362 $ 296 $ 1.69 18.3 % Three months ended June 30, 2024 (Dollars in millions, except per share amounts) Net sales Cost of Sales5 Gross Margin % Operating Expenses6 Operating Income Operating IncomeMargin % Non-Operating Expense (Income), net7 Income Before Income Taxes Net Income Attributable to Solventum Diluted EPS Effective Tax Rate GAAP $ 2,081 $ 944 54.6 % $ 893 $ 244 11.7 % $ 148 $ 96 $ 89 $ 0.51 7.3 % Non-GAAP Adjustments: Amortization of acquisition-related intangible assets — — — (86) 86 4.1 — 86 72 0.41 Restructuring costs (a) — (3) 0.2 — 3 0.2 — 3 2 0.01 Spin-off and separation-related costs (b) — (21) 1.0 (76) 97 4.7 (26) 123 104 0.61 Legal entity restructuring (c) — — — — — — — — 4 0.02 Non-GAAP $ 2,081 $ 920 55.8 % $ 731 $ 430 20.7 % $ 122 $ 308 $ 271 $ 1.56 12.2 % __________________________________________________________________________________ *Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum. (a) Severance, asset write-offs and related charges associated with certain restructuring programs. (b) Consists of costs specifically incurred in connection with the Company's separation from 3M. (c) Reflects the tax impacts for legal entity restructuring in connection with the separation from 3M. (d) Consists of charges and recoveries related to certain litigation matters. (e) Costs related to and tax impacts from the sale of the Company's Purification and Filtration business. 5 Cost of sales is the combination of cost of product and cost of software and rentals line items from the Consolidated Statements of Income and represents the total company cost of sales. 6 Operating expenses is the combination of selling, general and administrative expenses and research and development expenses from the Consolidated Statements of Income and represents the total company other operating expenses. 7 Non-operating expense (income), net is the combination of interest expense, net and other expense (income), net line items from the Consolidated Statements of Income and represents the total company non-operating expense. Six months ended June 30, 2025 (Dollars in millions, except per share amounts) Net sales Cost of Sales5 Gross Margin % Operating Expenses6 Operating Income Operating Income Margin % Non-Operating Expense (Income), net7 Income Before Income Taxes Net Income Attributable to Solventum Diluted EPS Effective Tax Rate GAAP $ 4,231 $ 1,942 54.1 % $ 1,922 $ 367 8.7 % $ 226 $ 141 $ 227 $ 1.30 (61.0) % Non-GAAP Adjustments: Amortization of acquisition-related intangible assets — — — (159) 159 3.7 — 159 135 0.77 Restructuring costs (a) — (11) 0.3 (15) 26 0.6 — 26 20 0.11 Spin-off and separation-related costs (b) — (60) 1.4 (210) 272 6.4 — 272 209 1.20 Certain litigation-related costs (d) — — — (27) 27 0.6 — 27 20 0.11 Sale of Purification and Filtration-related (e) — — — (31) 31 0.7 — 31 (80) (0.46) Non-GAAP $ 4,231 $ 1,871 55.8 % $ 1,480 $ 881 20.8 % $ 226 $ 655 $ 530 $ 3.03 19.0 % Six months ended June 30, 2024 (Dollars in millions, except per share amounts) Net sales Cost of Sales5 Gross Margin % Operating Expenses6 Operating Income Operating Income Margin % Non-Operating Expense (Income), net7 Income Before Income Taxes Net Income Attributable to Solventum Diluted EPS Effective Tax Rate GAAP $ 4,097 $ 1,788 56.4 % $ 1,684 $ 625 15.3 % $ 200 $ 425 $ 326 $ 1.88 23.3 % Non-GAAP Adjustments: Amortization of acquisition-related intangible assets — — — (173) 173 4.2 — 173 145 0.84 Restructuring costs (a) — (4) 0.1 (8) 12 0.3 — 12 8 0.05 Spin-off and separation-related costs (b) — (21) 0.5 (83) 104 2.5 (38) 142 120 0.69 Legal entity restructuring (c) — — — — — — — — 31 0.18 Non-GAAP $ 4,097 $ 1,763 57.0 % $ 1,420 $ 914 22.3 % $ 162 $ 752 $ 630 $ 3.64 16.2 % __________________________________________________________________________________ *Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum. (a) Severance, asset write-offs and related charges associated with certain restructuring programs. (b) Consists of costs specifically incurred in connection with the Company's separation from 3M. (c) Reflects the tax impacts for legal entity restructuring in connection with the separation from 3M. (d) Consists of charges and recoveries related to certain litigation matters. (e) Costs related to and tax impacts from the sale of the Company's Purification and Filtration business. 5 Cost of sales is the combination of cost of product and cost of software and rentals line items from the Consolidated Statements of Income and represents the total company cost of sales. 6 Operating expenses is the combination of selling, general and administrative expenses and research and development expenses from the Consolidated Statements of Income and represents the total company other operating expenses. 7 Non-operating expense (income), net is the combination of interest expense, net and other expense (income), net line items from the Consolidated Statements of Income and represents the total company non-operating expense. Free Cash Flow (non-GAAP measure): Free cash flow is not defined under U.S. GAAP. Therefore, it should not be considered a substitute for income or cash flow data prepared in accordance with U.S. GAAP and may not be comparable to similarly titled measures used by other companies. The company defines free cash flow as net cash provided by operating activities less purchases of property, plant and equipment. It should not be inferred that the entire free cash flow amount is available for discretionary expenditures. The company believes free cash flow is meaningful to investors as it is a useful measure of liquidity and the company uses these measures as an indication of the strength of the company and its ability to generate cash. Free cash flow varies across quarters throughout the year. Below find a recap of free cash flow. (Dollars in millions) Three months ended June 30, Six months ended June 30, Major GAAP Cash Flow Categories 2025 2024 2025 2024 Net cash provided by operating activities $ 169 $ 355 $ 198 $ 797 Net cash (used in) investing activities (110) (58) (224) (160) Net cash (used in) provided by financing activities (110) (396) (249) 66 Free Cash Flow (non-GAAP measure) Net cash provided by operating activities $ 169 $ 355 $ 198 $ 797 Purchases of property, plant and equipment (110) (58) (219) (160) Free cash flow 59 297 (21) 637 SOURCE Solventum WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Solventum Reports Second Quarter 2025 Financial Results

FAQ

Why Bullish?

How important is it?

Why Short Term?

Related Companies

Related News